NASDAQ:MGNX - MacroGenics Stock Price, Forecast & News

MacroGenics trades on the NASDAQ under the ticker symbol "MGNX."

MacroGenics Inc (NASDAQ:MGNX) posted its quarterly earnings data on Wednesday, November, 6th. The biopharmaceutical company reported ($0.91) earnings per share (EPS) for the quarter, topping the Thomson Reuters' consensus estimate of ($0.94) by $0.03. The biopharmaceutical company had revenue of $18.74 million for the quarter, compared to analysts' expectations of $23.33 million. MacroGenics had a negative return on equity of 59.67% and a negative net margin of 303.08%. View MacroGenics' Earnings History.

MacroGenics is scheduled to release their next quarterly earnings announcement on Tuesday, February 25th 2020. View Earnings Estimates for MacroGenics.

13 analysts have issued 12-month price targets for MacroGenics' stock. Their forecasts range from $6.00 to $50.00. On average, they anticipate MacroGenics' stock price to reach $23.90 in the next twelve months. This suggests a possible upside of 119.5% from the stock's current price. View Analyst Price Targets for MacroGenics.

13 Wall Street analysts have issued "buy," "hold," and "sell" ratings for MacroGenics in the last year. There are currently 2 hold ratings and 11 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for MacroGenics.

News articles about MGNX stock have been trending negative recently, InfoTrie Sentiment reports. InfoTrie identifies positive and negative media coverage by monitoring more than six thousand blog and news sources in real time. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores closest to five being the most favorable. MacroGenics earned a news sentiment score of -2.8 on InfoTrie's scale. They also gave news coverage about the biopharmaceutical company a news buzz of 0.0 out of 10, indicating that recent media coverage is extremely unlikely to have an effect on the stock's share price in the near term. View News Stories for MacroGenics.

MacroGenics saw a increase in short interest in the month of December. As of December 31st, there was short interest totalling 3,650,000 shares, an increase of 7.0% from the December 15th total of 3,410,000 shares. Based on an average trading volume of 557,900 shares, the short-interest ratio is presently 6.5 days. Currently, 8.3% of the shares of the stock are short sold. View MacroGenics' Current Options Chain.

Some companies that are related to MacroGenics include Arena Pharmaceuticals (ARNA), Ra Pharmaceuticals (RARX), Heron Therapeutics (HRTX), Synthorx (THOR), Aurinia Pharmaceuticals (AUPH), Turning Point Therapeutics (TPTX), Eidos Therapeutics (EIDX), Aimmune Therapeutics (AIMT), Prestige Consumer Healthcare (PBH), Xencor (XNCR), Cambrex (CBM), Ironwood Pharmaceuticals (IRWD), Principia Biopharma (PRNB), Pacira Biosciences (PCRX) and Zymeworks (ZYME).

Based on aggregate information from My MarketBeat watchlists, some companies that other MacroGenics investors own include AbbVie (ABBV), Exelixis (EXEL), Sangamo Therapeutics (SGMO), Gilead Sciences (GILD), NVIDIA (NVDA), Incyte (INCY), Karyopharm Therapeutics (KPTI), TherapeuticsMD (TXMD), Viking Therapeutics (VKTX) and Micron Technology (MU).

MacroGenics' stock is owned by a variety of of institutional and retail investors. Top institutional investors include Rhenman & Partners Asset Management AB (2.17%) and Alpine Global Management LLC (0.03%). Company insiders that own MacroGenics stock include Eric Blasius Risser, James Karrels, Jeffrey Stuart Peters, Lynn Cilinski, Matthew K Fust and Thomas Spitznagel. View Institutional Ownership Trends for MacroGenics.

MGNX stock was bought by a variety of institutional investors in the last quarter, including Rhenman & Partners Asset Management AB and Alpine Global Management LLC. View Insider Buying and Selling for MacroGenics.

Shares of MGNX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of MGNX stock can currently be purchased for approximately $10.89.

MacroGenics has a market capitalization of $533.17 million and generates $60.12 million in revenue each year. The biopharmaceutical company earns $-171,450,000.00 in net income (profit) each year or ($4.19) on an earnings per share basis. MacroGenics employs 364 workers across the globe.View Additional Information About MacroGenics.

The official website for MacroGenics is http://www.macrogenics.com/.

MacroGenics' mailing address is 9704 MEDICAL CENTER DRIVE, Rockville MD, 20850. The biopharmaceutical company can be reached via phone at 301-251-5172.